CA - Tetra Bio-Pharma ARDS-003 shows promise against COVID-19 in mice model

• Tetra Bio-Pharma ( OTCQB:TBPMF ) said its drug ARDS-003 showed antiviral activity against COVID-19 in preclinical studies in mouse model.
• The company said these studies explored the potential of ARDS-003 to increase survival following SARS-CoV-2 infection in humanized ACE2 mouse model.
• Data showed that compared to placebo, ARDS-003 dose dependently reduced signs of morbidity and mortality, including respiratory distress, Tetra said in an Aug. 10 press release.
• Under secondary goals, ARDS-003 also outperformed an antiviral drug in reducing multiple proinflammatory mediators (cytokines) involved in hyperinflammation and immune system dysfunction following viral infection, the company added.
• In addition, Tetra said that in a recent septic lung model, ARDS-003 produced a significant reduction of systemic cytokine/chemokine release, plus lung histology improved, peripheral immune hyper activation was reduced, and there was an improvement in capillary perfusion in lung tissue compared to controls.
• "ARDS-003, for example, could be used as an adjunct to Paxlovid or other antivirals to help reduce the morbidities associated with prolonged infection by SARS-CoV-2 and other viruses," said Tetra CEO and CRO Guy Chamberland.

For further details see: